This company has been acquired
Prometheus Biosciences Crecimiento futuro
Future controles de criterios 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Prometheus Biosciences.
Información clave
12.1%
Tasa de crecimiento de los beneficios
14.9%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 24.1% |
| Tasa de crecimiento de los ingresos | 70.2% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 13 Jun 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth
May 17
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation
Dec 03We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully
Aug 19Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M
Aug 11We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely
May 04Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases
Dec 08Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans
Nov 16Prometheus Biosciences: Precision Medicine For IBD
Sep 22Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2025 | 89 | -293 | -194 | -446 | 9 |
| 12/31/2024 | 7 | -232 | -173 | -302 | 10 |
| 12/31/2023 | 3 | -193 | N/A | -208 | 6 |
| 3/31/2023 | 4 | -151 | -136 | -133 | N/A |
| 12/31/2022 | 7 | -142 | -126 | -123 | N/A |
| 9/30/2022 | 7 | -133 | -107 | -104 | N/A |
| 6/30/2022 | 7 | -123 | -100 | -97 | N/A |
| 3/31/2022 | 6 | -108 | -76 | -74 | N/A |
| 12/31/2021 | 3 | -90 | -65 | -64 | N/A |
| 9/30/2021 | 3 | -69 | -48 | -47 | N/A |
| 6/30/2021 | 2 | -50 | -35 | -34 | N/A |
| 3/31/2021 | 2 | -38 | -42 | -42 | N/A |
| 12/31/2020 | 1 | -31 | -28 | -28 | N/A |
| 12/31/2019 | 1 | -17 | -20 | -20 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: RXDX is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: RXDX is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: RXDX is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: RXDX's revenue (70.2% per year) is forecast to grow faster than the US market (7.4% per year).
Ingresos de alto crecimiento: RXDX's revenue (70.2% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if RXDX's Return on Equity is forecast to be high in 3 years time